Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.

Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gröpper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V

Open source

DOI
10.1080/10428194.2017.1421758
Published
2018 Sep
Container
Leukemia & lymphoma
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2017.1421758,
  title = {Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.},
  author = {Almeida A and Fenaux P and Garcia-Manero G and Goldberg SL and Gröpper S and Jonasova A and Vey N and Castaneda C and Zhong J and Beach CL and Santini V},
  year = {2018},
  journal = {Leukemia \& lymphoma},
  doi = {10.1080/10428194.2017.1421758},
  url = {https://doi.org/10.1080/10428194.2017.1421758}
}

RIS

TY  - JOUR
TI  - Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
AU  - Almeida A
AU  - Fenaux P
AU  - Garcia-Manero G
AU  - Goldberg SL
AU  - Gröpper S
AU  - Jonasova A
AU  - Vey N
AU  - Castaneda C
AU  - Zhong J
AU  - Beach CL
AU  - Santini V
PY  - 2018
JO  - Leukemia & lymphoma
DO  - 10.1080/10428194.2017.1421758
UR  - https://doi.org/10.1080/10428194.2017.1421758
ER  - 

APA

A, A., P, F., G, G., SL, G., S, G., A, J., N, V., C, C., J, Z., CL, B., & V, S. (2018). Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2017.1421758

Source records